Journal article

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.

EJ Gibson, N Begum, I Koblbauer, G Dranitsaris, D Liew, P McEwan, AA Tahami Monfared, Y Yuan, A Juarez-Garcia, D Tyas, M Lees

ClinicoEconomics and Outcomes Research | Published : 2018

Abstract

Background: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect disease dynamics meaningfully. Materials and methods: This study explored the impact of incorporating immune-specific health states into economic models of I-O therapy. Two variants of the PSM and a Markov model were populated with data from one clinical trial in metastatic melanoma patients. Short-term modeled outcomes were benchmarked to the clinical trial data and a lifetime model horiz..

View full abstract